FDA Mandates Phase III Trial for uniQure's Huntington's Disease Gene Therapy, Blocking Market Approval and Sending Shares Down 33%

Stock News03-03 09:56

Gene therapy firm uniQure NV (QURE.US) saw its hopes for accelerated approval of its Huntington's disease candidate AMT-130 by the U.S. FDA dashed recently. The FDA has clearly informed the biopharmaceutical company that it must conduct a randomized, double-blind, sham-surgery controlled Phase III clinical trial. Following this news, the company's stock closed down approximately 33% on Monday. According to a press release from the company, uniQure had previously planned to seek approval based on data from a Phase I/II study compared with an external control. However, the FDA determined that the existing data is still insufficient to "serve as the primary evidence of effectiveness required to support a marketing application for AMT-130." uniQure stated it will request a Type B meeting with the FDA in the second quarter to discuss the subsequent development path. In a follow-up conference call, CEO Matthew Kapusta revealed that Phase I/II data showed the drug could slow disease progression by 75% and reduce the decline in total functional capacity by 60%. However, he also acknowledged that during a pre-BLA meeting last October, "the FDA had already indicated that the data submitted at that time... was unlikely to serve as the primary basis for supporting a BLA submission."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment